[{"id":"ad1d963e-b163-427e-be70-2d37437a6605","acronym":"","url":"https://clinicaltrials.gov/study/NCT07471841","created_at":"2026-03-28T01:44:38.203Z","updated_at":"2026-03-28T01:44:38.203Z","phase":"Phase 2","brief_title":"Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax","source_id_and_acronym":"NCT07471841","lead_sponsor":"Timothy Pardee","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Rezlidhia (olutasidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 05/01/2026","start_date":" 05/01/2026","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2026-03-13"},{"id":"8ecfd71e-09dc-439f-af05-bbb7a6382e68","acronym":"","url":"https://clinicaltrials.gov/study/NCT07130695","created_at":"2025-08-23T13:32:09.751Z","updated_at":"2025-08-23T13:32:09.751Z","phase":"Phase 1","brief_title":"Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation","source_id_and_acronym":"NCT07130695","lead_sponsor":"Virginia Commonwealth University","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rezlidhia (olutasidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 10/31/2025","start_date":" 10/31/2025","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2029","study_completion_date":" 10/31/2029","last_update_posted":"2025-08-19"},{"id":"42d928bf-01a8-4f38-bc3e-dbcbf7fa205e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06161974","created_at":"2023-12-08T22:16:35.701Z","updated_at":"2025-02-25T13:41:56.353Z","phase":"Phase 2","brief_title":"Study of Olutasidenib and Temozolomide in HGG","source_id_and_acronym":"NCT06161974","lead_sponsor":"Rigel Pharmaceuticals","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Rezlidhia (olutasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 06/01/2029","primary_completion_date":" 06/01/2029","study_txt":" Completion: 06/01/2035","study_completion_date":" 06/01/2035","last_update_posted":"2025-02-21"},{"id":"5f9fcf16-f9cb-4521-b187-17cb8a4a4f38","acronym":"2102-HEM-101","url":"https://clinicaltrials.gov/study/NCT02719574","created_at":"2021-01-17T17:25:33.100Z","updated_at":"2024-07-02T16:35:10.352Z","phase":"Phase 1/2","brief_title":"Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation","source_id_and_acronym":"NCT02719574 - 2102-HEM-101","lead_sponsor":"Forma Therapeutics, Inc.","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132 • Chr t(15;17)","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132 • Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • Rezlidhia (olutasidenib)"],"overall_status":"Completed","enrollment":" Enrollment 336","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 12/28/2023","primary_completion_date":" 12/28/2023","study_txt":" Completion: 01/24/2024","study_completion_date":" 01/24/2024","last_update_posted":"2024-04-10"},{"id":"7405703b-1424-4813-9c6b-eb10cb3f63eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03684811","created_at":"2021-01-18T18:03:56.956Z","updated_at":"2024-07-02T16:35:28.747Z","phase":"Phase 1/2","brief_title":"A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation","source_id_and_acronym":"NCT03684811","lead_sponsor":"Forma Therapeutics, Inc.","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • gemcitabine • azacitidine • Rezlidhia (olutasidenib)"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 05/24/2021","primary_completion_date":" 05/24/2021","study_txt":" Completion: 06/13/2022","study_completion_date":" 06/13/2022","last_update_posted":"2023-11-20"},{"id":"e7d8b286-5707-4030-9fcf-5b8294491103","acronym":"","url":"https://clinicaltrials.gov/study/NCT04013880","created_at":"2021-01-18T19:42:59.261Z","updated_at":"2024-07-02T16:36:43.617Z","phase":"Phase 1/2","brief_title":"ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia","source_id_and_acronym":"NCT04013880","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine) • Rezlidhia (olutasidenib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/27/2019","start_date":" 08/27/2019","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 03/31/2022","study_completion_date":" 03/31/2022","last_update_posted":"2020-07-07"}]